RJ Hamster
George W. Bush is inaugurated as the 43rd President of the United States. – Today’s Flashback
— Read on www.todaysflashback.com/george-w-bush-is-inaugurated-as-the-43rd-president-of-the-united-states/
RJ Hamster
The Daily Skrape – Nothing Is Beyond Our Comedic Crosshairs
— Read on www.dailyskrape.com/
RJ Hamster
January 20: England’s first Parliament gives commoners a voice, King George V’s death ends an era, and 52 Americans finally come home after 444 days captive.
— Read on this.dayinhist.com/posts/january-20-a-parliament-born-a-king-mourned-and-captives-freed
RJ Hamster
Peter,
MONDAY — 12-Jan-2026
Q. Which native Buffalo southpaw won more pitching victories in his career than any other lefty in any major league?
Hint: #1 No National League pitcher ever hit more home runs.
Hint: #2 He won the second ever Cy Young Award and did it at age thirty-six.
A. WARREN SPAHN [SABR Doc]
– Ans. You could say he “buffaloed” opponents 363 times and got the win for 6th place all-time. The next lefty in that list is Steve Carlton with 329.
– #1 Spahn’s 21-year career was only with NL teams, the Braves, the Mets & the Giants, but all 35 of his career homers were hit as a Brave. He hit 7 HR as a Boston Brave & 28 as a Milwaukee Brave. He left the Braves just 2 seasons before they relocated to Atlanta.
– #2 He was the first left-handed Cy Young Award winner when he won in 1957, 1 vote from being unanimous.
FCR – Eric Morrison, Myerstown, Pennsylvania
TUESDAY — 13-Jan-2026
Q. Which one-time Colorado Rockies pitcher holds the record for most major league home runs surrendered?
Hint: #1 Only four players can claim more seasons of major league service.
Hint: #2 In the same game last century, he got his one thousandth strikeout and one hundredth win.
A. JAMIE MOYER [SABR Bio]
– Ans. Moyer gave up 522 pitches to batters who scored before he next pitch was thrown. He pitched for COL in 2012.
– #1 He was on one of 8 major league teams for a total of 25 years of service. The only players with more are Nolan Ryan & Cap Anson (27); Tied for 3rd are Deacon McGuire & Tommy John (26); Then Rickey Henderson, Eddie Collins, Bobby Wallace, Charlie Hough & Moyer each played 25 years.
– #2 Pitching for SEA in Cleveland on 27-Apr-1988, Moyer pitched six innings, struck out David Bell in the 6th and got the win for his 100th. He got 169 more wins before retiring.
FCR – Warren Kent, Whitehall, Michigan
WEDNESDAY — 14-Jan-2026
Q. Which one-time Orioles pitcher had led the majors in wins for the Yankees in his second seasons with them?
Hint: #1 Seven years earlier, he led the majors in ERA and ERA+.
Hint: #2 In each of those seasons, he finished second in Cy Young Award voting.
– Ans. Key joined NYY10-Dec-1992 via free agency. He led MLB with 17 W in strike-shortened 1994. He finished with BAL 1997 & 1998.
– #1 With TOR in 1987, Key’s 2.76 ERA & 164ERA+ both led MLB.
– #2 In 1987, Key finished behind Roger Clemens for AL CYA. In 1994, it was former teammate David Cone who won.
FCR – Shaun Montana, Medway, Massachusetts
THURSDAY — 15-Jan-2026
Q. Who was the first pitcher to pick off Rickey Henderson?
Hint: #1 He still leads all Kansas City Royals pitchers in games started, career wins, innings pitched and batters faced.
Hint: #2 In spite of his reliable workmanlike efforts over fifteen seasons, he was never selected to All-Star team.
A. PAUL SPLITTORF [SABR Bio]
– Ans. In Henderson’s 3rd MLB game on 26-Jun-1979, he drew a walk as the leadoff batter of the 3rd inning. On the next pitch, he broke for second, but Splittorf threw to 1st base and he was caught in a P-1B-SS-1B rundown, George Scott & Freddie Patek being the infielders involved.
– #1 Splittorf finished with 392 GS, 166 W, 2,554⅔ IP & 10,829 BF.
– #2 He did received CYA votes in 1978.
FCR – Mark Pattison, Washington, DC
FRIDAY — 16-Jan-2026
Q. Who was the first pitcher born outside the United States to throw a regular-season perfect game for a team domiciled outside the United States?
Hint: #1 His perfecto didn’t come until the sixteenth of his twenty-three seasons in the majors.
Hint: #2 He enjoyed the company of many of the game’s best players, including Hall o Famers such as Reggie Jackson, Randy Johnson and Jim Thome.
Hint: #3 He is the only native of his country to lead the majors in pitching victories for a season.
A. DENNIS MARTINEZ [SABR Bio]
– Ans. Martinez is famously a native of Nicaragua & while employed by the Montreal Expos, threw a perfect game against LAD in LA on 28-Jul-1991.
– #1 He debuted with BAL in 1976 and finished in 1998 with ATL. He played with MON, CLE & SEA between those 2.
– #2 Hall of Fame teammates included Jackson, Jim Palmer, Eddie Murray (a future perfect game victim), Cal Ripken, Tim Raines, Andre Dawson, Johnson, Thome, Ken Griffey Jr, Greg Maddux, Edgar Martinez (no relation), Chipper Jones, Tom Glavine, John Smoltz & possibly… Andruw Jones (?).
– #3 In the shortened season of 1981, Martinez led with 14 W for BAL. His Ws tied with those of Steve McCatty, Pete Vuckovich & Hall of Famers Tom Seaver & Jack Morris, all 4 natives of the USA.
FCR – Jake Bell, Santa Fe, New Mexico
SATURDAY — 17-Jan-2026
Q. Which onetime St. Louis Cardinal player was the first Los Angeles Dodger pitcher to win the Rookie of the Year Award?
Hint: #1 He only won the Cy Young Award once, but he won it unanimously.
Hint: #2 He hit his first career home run off Tom Seaver.
A. RICK SUTCLIFFE [SABR Bio]
– Ans. In 1979, Sutcliffe was LAD’s 1st pitcher to be ROY. (There had been 2 in Brooklyn.) He ended his playing career with STL in 1994.
– #1 In 1984, he was the NL CYA and took all the first-place votes
– #2 HR off Seaver = 25-May-1979, the 1st of his 4 HR in MOB.
FCR – Scott Morissey, Hamilton, Ontario
SATURDAY BONUS — 08-Mar-2025
Q. Who was the team’s pitching coach when his star reliever gave up the most famous home run ever hit in Toronto?
Hint: #1 There’s a statue of him in Cooperstown commemorating his most famous accomplishment.
Hint: #2 He taught Cy Young Award-winning Fran k Viola a career-changing changeup.
A. JOHNNY PODRES [SABR Bio]
– Ans. Podres was the Phillies’ pitching coach 1991-1996. Here is the HR in question.
– #1 Click here for the Hall of Fame statue.
– #2 Viola was 11-25 in his first 2 seasons, then had 6 straight years over .500 including the 1988AL CYA.
FCR – Jesse Asbury, Norman, Oklahoma
SUNDAY — 18-Jan-2026
Q. Who spent his whole career in the Cy Young Award Era, threw a no-hitter and a perfect game, yet received only a single CYA vote in his whole career?
Hint: #1 He is the only pitcher who surrendered an inside-the-park home run to Hank Aaron.
Hint: #2 He played for both leagues and served in both chambers.
A. JIM BUNNING [SABR Bio]
– Ans. Bunning threw a no-hitter for DET 20-Jul-1958(1), a perfect game for PHI on 21-Jun -1964(1). Then in 1967, he received one (1) vote for the NL CYA that SFG’s Mike McCormick won that year.
– #1 On 10-May-1967(1), Aaron’s only hit of the game was a 2-run IPHR With Bunning on the mound.
– #2 Bunning played 9 years in the AL & 8 years in the NL. He represented Kentucky in the U.S. House of Representatives for four 2-year terms & in the U.S. Senate for two six-year terms.
FCR – Jim Lovelace, Kent, Ohio
Weekly theme: Select first-day starting pitchers in their team’s new stadium, those built since WWII
County Stadium………….. MLN… 14-Apr-1953.. W……….. Spahn… 100.1
Veterans Stadium……….. PHI….. 10-Apr-1971.. W……….. Bunning.. 59.4
Safeco Field………………. SEA…. 15-Jul-1999… L………… Moyer….. 49.8
SkyDome…………………… TOR… 05-Jun-1989. L………… Key……… 48.9
Jacobs Field………………. CLE…. 04-Apr-1994.. W……….. Martinez. 48.7
OPCY……………………….. BAL…. 06-Apr-1992.. W……….. Sutcliffe… 33.9
Dodger Stadium…………. LAD…. 10-Apr-1962.. L………… Podres… 29.8
Veterans Stadium……….. PHI….. 10-Apr-1971.. W……….. Bunning.. 59.4
Kauffman Stadium………. KCR… 04-Apr-1973.. W……….. Splittorf… 23.0
First Correct Respondent identifying theme – Nobody
If you know someone who would enjoy receiving daily Horsehide Trivia questions, have them click here: Horsehide Trivia or do it on their behalf.
Click here => THIS WEEK’s quiz, compete with questions, hints, answers & even incorrect guesses.
Scroll back to see previous Horsehide Trivia posts as far back as 2010. Quizzes before that may also be available upon request.
Horsehide Trivia encourages independent research. ⚾️
~ D. Bruce Brown
Horsehide Trivia | 8830 Sandrope Court | Columbia, MD 21046 US
RJ Hamster
Momentum Trackers Just Lit Up — Here’s Why (From Stock News Trends)
Written by Jeffrey Neal Johnson on January 16, 2026
Unusual market activity is often the first sign that big changes are coming to a stock. Professional traders and large institutions frequently use the options market to place high-conviction bets before major news becomes public. On Jan. 15, 2026, AbbVie Inc. (NYSE: ABBV) experienced one of these unusual events. Daily call option volume for the healthcare giant surged to 2,599% of its historical average. This increase in bullish activity suggests that the smart money is positioning for a significant move. With the stock trading near $216.66, this volume suggests a belief that a breakthrough or a positive financial surprise is imminent.
Traders use call options to profit from a rising stock price. When volume spikes by more than 2,500%, it is rarely a coincidence. Institutional investors often have access to deep research and sophisticated models that help them anticipate market shifts. By examining the upcoming calendar, we can identify several key factors that likely triggered this sudden rush of capital into AbbVie.
What If Washington Declared That: YOUR Money ISN’T Actually Yours?
Sounds insane, but that’s exactly what the Department of Justice just admitted in court—claiming cash isn’t legally your property.
What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.Get your free guide now by clicking here >>
The most immediate reason for the surge in options is the upcoming fourth-quarter 2025 earnings report. AbbVie is estimated to release these results on Feb. 4, 2026. Institutional confidence is high because the company has established a pattern of excellence over the past year. In every single quarter of 2025, AbbVie beat analyst estimates and raised its full-year guidance. Currently, the company expects adjusted earnings per share (EPS) to land between $10.61 and $10.65 for the full year.
Investors are particularly impressed with how the company has managed its product transitions. For years, the market worried that the decline of the blockbuster drug Humira would hurt the bottom line. However, the latest data shows that the plan to replace that revenue is working.
If management provides a strong outlook for 2026 during the February call, it would justify the massive volume of call options currently in play. Traders appear to be betting that AbbVie’s growth stars will continue to outperform, leading to another beat-and-raise scenario.
Strategic growth and a new regulatory agreement are also driving the bullish sentiment. On Jan. 12, 2026, AbbVie reached a voluntary agreement with the federal administration for a period of three years. This pact removes many of the political risks that have weighed on drug companies. Under this deal, AbbVie committed to a $100 billion investment in U.S. research, development, and manufacturing over the next 10 years. In exchange, the company secured a three-year exemption from new tariffs and federal drug-pricing mandates. This agreement provides institutions with the policy certainty they need to buy large amounts of stock with confidence.
This regulatory win is occurring just as AbbVie enters the high-growth obesity market. On Jan. 15, 2026, the company announced that it had completed its first human trial for GUB014295. This drug is a long-acting amylin analog designed to treat obesity. The obesity market is currently one of the fastest-growing sectors in healthcare.
By entering this space, AbbVie could see multiple expansions. This means investors might be willing to pay more for every dollar of the company’s earnings because it is now competing in a high-growth category. Additionally, the company is awaiting an FDA decision on its Parkinson’s disease candidate, Tavapadon, in the first half of 2026. These clinical goals are likely what options traders are trying to get ahead of.
A former hedge fund manager known for cutting through market noise is briefly opening access to his flagship trading strategy. In a short demo, he explains how his “One Ticker” approach works — and how readers can access the full service for a year at a steep discount.Watch the brief demo here
While new growth projects could drive a higher price, AbbVie’s fundamental metrics provide a strong safety net. Abbvie’s analyst community currently holds a Moderate Buy consensus on the stock. The average 12-month price target is $247.84, suggesting an upside of about 14% from today’s price. The stock’s forward price-to-earnings ratio (P/E) of 17.60 is considered attractive, especially as the company adds more high-growth drugs to its portfolio.
Income-oriented investors also find security in AbbVie’s status as a Dividend King. The company has increased its dividend for 53 consecutive years. The current quarterly dividend is $1.73 per share, yielding around 3.19% and resulting in an annual dividend of $6.93. Large institutions own 70.23% of the company, showing that they value the stock for its reliable income and defensive qualities. This high level of institutional ownership creates a valuation floor, meaning the stock is less likely to drop significantly while traders wait for the next big catalyst.
The sudden 2,600% surge in call option volume is a clear sign that sophisticated investors are preparing for a breakout. This activity reflects a convergence of positive events: a stabilized regulatory environment, a major entry into the obesity market, and consistent earnings growth. AbbVie has successfully moved past its reliance on legacy drugs and emerged as a diversified leader in immunology and metabolic health.
For investors seeking a mix of reliable income and the potential for significant price increases, the current market signals are hard to ignore. The smart money is moving toward AbbVie, suggesting that the upcoming February earnings report could be the start of a new rally.
Recommended Stories
Did you like this article?
Thank you for subscribing to Earnings360, a morning newsletter that summarizes quarterly earnings for public companies that trade on U.S. markets.
If you need help with your account, feel free to contact MarketBeat’s South Dakota based support team at contact@marketbeat.com.
If you no longer wish to receive email from Earnings360, you can unsubscribe.
© 2006-2026 MarketBeat Media, LLC.
345 N Reid Place #620, Sioux Falls, South Dakota 57103-7078. United States of America..
Just For You: Refund From 1933: Trump’s Reset May Create Instant Wealth (From American Hartford Gold)
RJ Hamster
| UnsubscribeDo NOT buy gold until you see this (From Digest Publishing)3 Elite ETFs for Compound-Focused InvestorsWritten by Ryan Hasson on January 17, 2026 Quick LookOption-overlay ETFs are reshaping income-focused compounding, turning market volatility into double-digit cash flow that can be reinvested for the long term.SPYI and QQQI offer high-yield exposure to the S&P 500 and Nasdaq 100, combining core index participation with tax-aware or aggressive income strategies.JEPQ provides an institutional-grade alternative, pairing active management with a 10%+ yield for investors seeking scalable, durable income in tech-heavy markets.For investors focused on building long-term, compound returns, the strategy has shifted in recent years. Whilst buying a high-quality S&P 500 ETF still remains a Buffett-approved approach, several new options have recently become available for compound-focused investors. Investors can now capture high-yield income through sophisticated option-overlay ETFs. These funds keep their usual index stock exposure but sell options (often call options) on that index to collect premium income, which is then paid out as frequent distributions. These distributions often far exceed traditional dividends, turning the volatility of the S&P 500 and the Nasdaq-100 into a somewhat predictable cash flow engine. By reinvesting these yields, an investor can accelerate their share count growth regardless of whether the broader market is moving sideways or upward.Let’s delve into three popular ETFs that aim to deliver aggressive returns to their shareholders.HUGE gold prediction (Ad)January 28 could be a critical date for gold Most Americans missed this big story, but 1 in 5 states have now made gold and silver coins legal tender. It’s just one reason why so many predict gold will soon hit $5,000. And why you need to check out this strategy for gold (less than $50 to get started) before January 28.Click here for the full details.SPYI: Core Market Exposure With a Tax-Efficient TwistThe NEOS S&P 500 High Income ETF (BATS: SPYI) is especially relevant for those seeking a balance between the stability of the S&P 500 and high-octane income.As of mid-January 2026, SPYI is trading near $53 with an exceptional dividend yield of 11.61%. The fund manages $7.1 billion in assets, and distinguishes itself through a rules-based approach that uses SPX Index options.This strategy is particularly insightful for tax-conscious investors because index options are classified under Section 1256 contracts, which typically qualify for a 60/40 blend of long-term and short-term capital gains treatment.This tax efficiency makes SPYI a more durable choice for non-retirement accounts than standard covered-call funds, which may generate higher tax liabilities.And no surprises in terms of its top holdings, which closely mirror the S&P 500. Mega-cap technology giants like NVIDIA, Apple, Microsoft, and Alphabet account for almost 20% of its holdings.QQQI: Capturing Tech Growth and Double-Digit YieldsNow, for those willing to lean into the technology sector’s momentum and heightened volatility, the NEOS Nasdaq-100 High Income ETF (NASDAQ: QQQI) offers an even more aggressive yield profile.The QQQI ETF has a whopping 13.71% yield, paying out an annual dividend of $7.44.How is that possible? The fund utilizes a data-driven strategy to sell out-of-the-money call options on the Nasdaq 100.This approach allows investors to participate in a portion of the tech sector’s upside while simultaneously banking a monthly distribution that can be used to purchase more shares.Yes, the upside is capped, but the income is real. The fund was only launched in 2024, but over the past 12 months, it has gained popularity.It trades an average of 4.45 million shares daily, and over the last twelve months, institutions have purchased over $16 million worth of the ETF, versus just $1.48 million in outflows. 5 Stocks That Could Double in 2026 (Ad)While everyone’s making predictions about what might happen in 2026, we’ve identified 5 stocks with catalysts that are already locked and loaded. These aren’t hopes or projections. These are scheduled events, signed contracts, and approved projects that will play out over the next 12 months. The difference between 100% gains and missing out completely? Positioning before 2026 arrives.Click here to get your free copy of this reportJEPQ: Institutional Precision in the Nasdaq SpaceThe JPMorgan Nasdaq Equity Premium Income ETF (NASDAQ: JEPQ) is one of the largest and most popular income ETFs, with $33.3 billion assets under management (AUM). It represents the institutional standard for the equity-income category. Its dividend yield of 10.42% is impressive, along with a relatively low net expense ratio of 0.35%.Unlike the two NEOS funds discussed above, which use a more rigid rules-based option strategy, JEPQ utilizes active management and Equity Linked Notes (ELNs) to generate income.That strategy allows JPMorgan portfolio managers to exercise discretion, potentially avoiding yield traps that can arise during rapid market shifts.For the compound-focused investor, JEPQ offers institutional security and scale, ensuring the income engine remains operational even during periods of extreme market stress. Technology names dominate the ETF’s holdings, with 39% exposure to the tech sector.This is largely due to the monstrous market valuation of its top seven holdings, which are, of course, the Magnificent Seven.Bottom Line: High Income, Real TradeoffsOption-overlay ETFs like SPYI, QQQI, and JEPQ can be powerful tools for investors who prioritize monthly income and reinvestment-driven compounding, but they come with real tradeoffs—especially capped upside in strong rallies and distributions that can vary with volatility. The best fit depends on your risk tolerance, tax situation, and whether you’re optimizing for steady cash flow or maximum long-term total return.Read this article online ›Read MoreHigh Risk, High Reward: 3 Healthcare Stocks to Watch in 2026Executive Order 14330: Trump’s Biggest Yet (From The Oxford Club)3 “Forever Stocks” to Hold When the Market Won’t Sit StillTicker Revealed: Pre-IPO Access to “Next Elon Musk” Company (From Banyan Hill Publishing)3 Innovative Crypto ETFs That May Surprise in 20262 Buffett Stocks to Load Up On—And 1 to DitchCan’t Choose Between Silver and Gold? These ETFs Hold Both Did you enjoy this article? Thank you for subscribing to DividendStocks.com‘s daily newsletter for dividend and income investors that covers ex-dividend stocks, new dividend declarations, dividend stock ideas, and the latest market news. If you have questions or concerns about your account, feel free to email our South Dakota based support team at contact@marketbeat.com. If you no longer wish to receive email from DividendStocks.com, you can unsubscribe. © 2006-2026 MarketBeat Media, LLC. 345 North Reid Place, Sixth Floor, Sioux Falls, South Dakota 57103-7078. United States of America..Today’s Featured Link: 7 High-Yield Dividend Stocks You Need to See (Click to Opt-In) |
RJ Hamster
| UnsubscribeA message from our partners at i2i Marketing Group, LLCWhat Comes After Solar?Early capital doesn’t chase yesterday’s stories – it looks for what comes next. And as solar power matures, a new opportunity is forming beyond installation and generation.More than 7 billion solar panels are already in use worldwide. As that infrastructure ages, there’s a hidden gap quietly creating a real opportunity.Markets tend to react after these shifts become obvious. Early movers position before they do.See the how this is all taking shape: Today’s Exclusive NewsThe AI Tech Paradox: Insiders Sell, the Case for Buying Gets StrongerReported by Thomas Hughes. Originally Published: 1/5/2026. In BriefInsiders sell AI-related tech stocks after massive run-ups, but investors shouldn’t worry.Underlying trends suggest these stocks, including NVIDIA, will continue to advance or stage rebounds in 2026.Institutions and analysts accumulated in 2025, pointing to solid upside in 2026.Insiders are selling some tech stocks critical to AI, including NVIDIA — a sign of potential risk, but not a reason to panic. The stocks on this list climbed by double digits in 2025, giving employees who receive share-based compensation ample incentive to sell.The roughly 30% to 115% gains posted by year-end created opportunities to take profits, diversify and reallocate capital, and cover the taxes that come with large equity payouts.Trump Did WHAT?? (Ad)While President Trump’s official salary is $400,000 per year… his tax returns reveal he’s been collecting up to $250,000 PER MONTH from one hidden source. Until recently, most Americans couldn’t touch the type of investment that makes up this investment. But thanks to Executive Order 14330, that just changed. If you love investing in disruptive new companies…Discover how to invest in the fund Trump uses to collect this income >>Although insiders — from CEOs and CFOs to directors and large shareholders — have been selling, investors should focus on what’s driving these big price moves and how other market participants are responding. In most cases, AI and its impact across the tech stack are the primary drivers, and the market overall is accumulating shares.NVIDIA Insiders Sell Heavily in 2025: GPU Demand Remains HotNVIDIA (NASDAQ: NVDA) insiders, including CEO Jensen Huang, sold heavily in 2025, with activity continuing through the end of December. Even after those sales, insiders still own a meaningful 4.2% stake, and other market groups are accumulating. Data tracked by InsiderTrades.com shows that institutions contributed to volatility in Q4 2025 by selling on balance, but the year’s overall activity remains bullish.Institutions bought on balance in the first three quarters of the year, purchasing more than $2.50 for each $1 sold, and ended the year controlling over 65% of outstanding shares. Activity in the first week of 2026 extended the bullish trend, with institutions buying roughly $2.85 for each $1 sold. Analysts have been raising price targets and, on consensus, forecast about 40% upside for 2026.CoreWeave Insiders Cap Gains in 2025: GPU Capacity Is Sold OutCoreWeave (NASDAQ: CRWV) insiders, who own about 25% of the company, capped gains in 2025 through sales. The stock rallied sharply midyear, creating an irresistible opportunity for insiders to monetize gains. Although the share price has pulled back from its highs, it still trades roughly 100% above its IPO price and appears positioned to rebound.Institutions, which own about 30% of the stock, bought the Q4 dip, netting more than $2.00 in purchases for each $1 sold. Meanwhile, analysts have tightened forecasts around consensus in the second half of 2025, leaving a robust 55% upside baked into estimates. CoreWeave’s 2025 catalysts include monetizing its sold-out AI capacity and continuing expansion plans.Broadcom Insiders Take Profits: Custom GPUs, ASICs, and Infrastructure in High DemandBroadcom (NASDAQ: AVGO) is well positioned to supply custom AI infrastructure, including GPUs, ASICs and platforms. The stock finished the year up nearly 50% despite insider selling, which may continue into 2026. Institutions, which own more than 75% of shares, accumulated in 2025 and extended that trend in the first week of 2026.If that buying persists, the uptrend is likely to continue and analysts are increasingly supportive. Results and guidance prompted analysts to upgrade the consensus rating from Moderate Buy to Buy and to raise price targets significantly — in some cases by more than 100%. The analysts’ consensus target of $437 in early January implies roughly 27% upside from key support levels; the high-end range implies further upside beyond that.Credo Technologies Rises 90%, Insiders Sell: All the GPU Racks Need to Be ConnectedCredo Technologies (NASDAQ: CRDO) emerged as a preferred provider of optical, high-speed, low-latency connectivity solutions for GPU and datacenter applications in 2025. The stock surged more than 100% at its peak and finished the year up about 90%. Insider selling trimmed late-year gains, but institutions and analysts were accumulating and point to solid upside in 2026.Institutions own more than 80% of the stock, buying on balance in each quarter of 2025 and continuing to purchase in the first week of 2026. Analysts likewise rate the stock a Buy and raised price targets throughout the year, leaving the consensus near $207 at year-end — implying more than 50% upside if reached.Palantir Rises as Enterprise Leans Into AI: Leading the Monetization of AI ApplicationsPalantir (NASDAQ: PLTR) has been among the more successful companies at monetizing AI. Its business has been fueled by private and government demand, growing service penetration and accelerating digital adoption globally. Insiders sold throughout the year, contributing to greater volatility in H2 2025, but that selling has been offset by institutional and analyst activity.Institutions bought on balance every quarter of 2025, purchasing nearly $2 for each $1 sold, and extended that buying into the first week of 2026. Analysts, who were initially slow to recognize Palantir’s potential, are now in a robust upgrade cycle. Numerous year-end price-target increases lifted consensus by more than 300% over 12 months. The consensus implies fair value in early January, while high-end targets suggest roughly 20% upside from key support levels — with new all-time highs possible. This message is a paid sponsorship for i2i Marketing Group, LLC, a third-party advertiser of MarketBeat. Why was I sent this email content?. We are not securities dealers or brokers, investment advisers or financial advisers, and you should not rely on the information herein as investment advice. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the profiled company’s SEC and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. If you need assistance with your account, feel free to contact MarketBeat’s South Dakota based support team at contact@marketbeat.com. If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here. Copyright 2006-2026 MarketBeat Media, LLC. 345 N Reid Place #620, Sioux Falls, South Dakota 57103-7078. USA.. |
RJ Hamster
| January 20, 2026 | Read Online | Send FeedbackGood morning. Here’s your Tuesday playlist:MORNING BRIEFDOJ Probing ICE Protesters Who Disrupted Church Service in Minnesota🎧 Listen on Apple PodcastsWhat could make your listening experience better? Send us a line at podcasts@epochtimes.us New to our newsletter? Subscribe here to listen to our reporters on the ground. Prefer a different podcast platform? Pick one here.🎙️ MORE PODCASTSThe nation’s pressing topics deciphered by our journalists from the podcast desk.CROSSROADS1,500 Troops on Standby for Deployment to MinnesotaTroops may be deployed to Minnesota to help quell growing protests calling to block ICE deportations. The Pentagon has confirmed they are prepared to carry out orders if President Donald Trump carries out a plan to invoke the Insurrection Act. 🎧 Listen → THE REPORTBehind the Group That Controls Chinese Students in AmericaFight with all their might for the motherland.’ Chinese students are pressured into advancing Beijing’s interests in America. 🎧 Listen → CHINA WATCHWhat’s China’s Stake in Iran? It’s Not Oil.U.S. President Donald Trump has called for “new leadership in Iran.” The country’s economy is on the brink of collapse. What began as an economic protest quickly escalated into a nationwide anti-regime movement. 🎧 Listen → Thanks for tuning in!Today’s newsletter was put together by Ivan Pentchoukov, Lina Skorbach and Kenzi Li. Send them your feedback at podcasts@epochtimes.us. 📅 Podcast Schedule:American Thought Leaders – Tuesday, Thursday, SaturdayCalifornia Insider – Tuesday, Wednesday, Thursday, SaturdayChina Watch – TuesdayCrossroads – Monday–ThursdayFacts Matter – Tuesday & ThursdayMorning Brief – WeekdaysThe Report – Weekdays☝ Click on the links above to pick your favorite podcast platform. Did someone forward this newsletter to you? Subscribe here. Copyright © 2026 The Epoch Times, All rights reserved. Our mailing address is: The Epoch Times. 229 W. 28 St. Fl. 7 New York, NY 10001 | Contact Us The Audio Room newsletter is one of the best ways to receive the most up-to-date information. Manage your email preferences here or unsubscribe from The Audio Room here. |
RJ Hamster
  Sign inFeeling run down after the holidays? We’re here 24/7—get care now.January Health BeatDeclutter your digital worldOur screens have become a huge part of our daily lives, but the “digital clutter” of endless notifications and overflowing inboxes can take a toll. Starting fresh in 2026 doesn’t just apply to your home—your digital world can benefit from a little refresh too.Simplify nowTrending this weekSet intentions with a vision boardHelp turn your goals into reality by crafting a vision board that inspires action, using photos, words and magazine cutouts.Read moreExplore more articles, recipes and resources in our Health Library.Your care options include24/7 CareGet 24/7 care for non-urgent conditions. Get care nowMental HealthFind a mental health provider who is right for you. Schedule a visitNutritionTalk to a registered dietitian for help managing nutrition. Schedule a visitDermatologyUpload photos to get a treatment plan for skin conditions. Upload photos nowDownload the Teladoc Health appView all your virtual care options—and take care on the go.  “I’ve been very pleased with Teladoc Health because it’s convenient, affordable, fast and still provides quality care.”Kim T.The testimonials, opinions and statements reflect one member’s personal experience with Teladoc Health. Results and experiences may vary from person to person. The testimonials are voluntarily provided and are not paid.© Teladoc Health, Inc. All rights reserved. Teladoc Health marks and logos are owned by Teladoc Health, Inc. All programs and services are subject to applicable terms and conditions. 155 East 44th Street, Suite 1700, New York, NY 10017Privacy policy | Unsubscribe160830 |
RJ Hamster